瑞普生物
(300119)
| 流通市值：53.15亿 | | | 总市值：74.14亿 |
| 流通股本：3.34亿 | | | 总股本：4.66亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,248,962,053.98 | 1,587,164,776.49 | 994,096,256.27 | 442,780,482.14 |
| 营业收入 | 2,248,962,053.98 | 1,587,164,776.49 | 994,096,256.27 | 442,780,482.14 |
| 二、营业总成本 | 1,874,332,565.39 | 1,314,397,482.78 | 823,889,058.32 | 361,812,573.71 |
| 营业成本 | 1,131,511,619.1 | 778,537,880.9 | 477,381,286.96 | 217,072,435.66 |
| 税金及附加 | 22,203,992.12 | 15,144,157.78 | 10,239,808.25 | 3,685,790.15 |
| 销售费用 | 370,957,942.24 | 266,621,217.9 | 176,385,967.39 | 70,188,590.29 |
| 管理费用 | 157,777,328.52 | 115,568,835.73 | 73,603,846.7 | 33,672,025.1 |
| 研发费用 | 172,941,860.8 | 124,183,791.04 | 76,985,881.15 | 32,060,179.48 |
| 财务费用 | 18,939,822.61 | 14,341,599.43 | 9,292,267.87 | 5,133,553.03 |
| 其中:利息费用 | 24,326,885.33 | 18,361,455.76 | 12,312,317.49 | 6,350,329.91 |
| 其中:利息收入 | 5,613,792.99 | 4,132,674.48 | 2,943,375.84 | 1,521,081.13 |
| 加:公允价值变动收益 | 61,259,889.12 | 29,776,681.13 | 21,961,740.08 | 14,764,322.05 |
| 加:投资收益 | 15,150,590.17 | 23,602,091.27 | 21,393,115.52 | -300,766.25 |
| 资产处置收益 | 114,086,414.4 | 137,384.99 | 76,697.88 | - |
| 资产减值损失(新) | 580,187.35 | 934,206.98 | 772,146.88 | 541,387.14 |
| 信用减值损失(新) | -28,977,886.5 | -21,454,014.5 | -9,118,488.96 | -4,624,161.86 |
| 其他收益 | 28,501,552.84 | 20,954,764.33 | 10,597,858.94 | 7,185,565.7 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 565,230,235.97 | 326,718,407.91 | 215,890,268.29 | 98,534,255.21 |
| 加:营业外收入 | 2,958,653.37 | 489,384.84 | 115,513.82 | 107,224.56 |
| 减:营业外支出 | 1,508,835.97 | 1,122,261.11 | 899,433.43 | 458,148.06 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 566,680,053.37 | 326,085,531.64 | 215,106,348.68 | 98,183,331.71 |
| 减:所得税费用 | 55,663,328.19 | 31,184,567.68 | 21,632,435.68 | 10,680,506.09 |
| 六、净利润 | 511,016,725.18 | 294,900,963.96 | 193,473,913 | 87,502,825.62 |
| 持续经营净利润 | 511,016,725.18 | 294,900,963.96 | 193,473,913 | 87,502,825.62 |
| 归属于母公司股东的净利润 | 452,942,064.27 | 273,697,993.12 | 178,271,133.74 | 80,823,461.46 |
| 少数股东损益 | 58,074,660.91 | 21,202,970.84 | 15,202,779.26 | 6,679,364.16 |
| (一)基本每股收益 | 0.98 | 0.59 | 0.38 | 0.17 |
| (二)稀释每股收益 | 0.98 | 0.59 | 0.38 | 0.17 |
| 九、综合收益总额 | 511,016,725.18 | 294,900,963.96 | 193,473,913 | 87,502,825.62 |
| 归属于母公司股东的综合收益总额 | 452,942,064.27 | 273,697,993.12 | 178,271,133.74 | 80,823,461.46 |
| 归属于少数股东的综合收益总额 | 58,074,660.91 | 21,202,970.84 | 15,202,779.26 | 6,679,364.16 |
| 公告日期 | 2024-03-30 | 2023-10-26 | 2023-08-26 | 2023-04-27 |
| 审计意见(境内) | 标准无保留意见 | | | |